CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into a long-term loan and security …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has hired Olivia Ware as its Chief Commercial …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced that it has reached an agreement to settle its consolidated stockholder …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it reached a successful agreement to settle the consolidated …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has selected its next drug, designated DK049, for …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has reached its enrollment target of 400 patients …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has achieved its target enrollment of 28 patients …
Stocks in the biotech sector are notoriously volatile pending financial earnings results and new drug trials. Analysts weigh in on CytRx Corporation (NASDAQ:CYTR) …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months endedSeptember 30, 2015, and …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that a poster titled “A Phase 1b/2 Study of Aldoxorubicin …
